The recently passed Inflation Reduction Act (IRA) was hailed by supporters as a major milestone for reducing costs across a range of sectors, including prescription drug prices. The Rare Access Action Project (RAAP) was involved in the debate from the beginning warning that certain provisions could have detrimental effects on innovation, particularly in the orphan…
